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This paper examines whether screen-detected breast cancer confers additional prognostic benefit to the patient, over and above that
expected by any shift in stage at presentation. In all, 5604 women (aged 50–70 years) diagnosed with invasive breast cancer between
1998 and 2003 were identified by the Eastern Cancer Registration and Information Centre (ECRIC) and mammographic screening
status was determined. Using proportional hazards regression, we estimated the effect of screen detection compared with
symptomatic diagnosis on 5-year survival unadjusted, then adjusted for age and Nottingham Prognostic Index (NPI). A total of 72% of
the survival benefit associated with screen-detected breast cancer can be accounted for by age and shift in NPI. Survival analysis by
continuous NPI showed a small but systematic survival benefit for screen-detected cancers at each NPI value. These data show that
although most of the screen-detected survival advantage is due to a shift in NPI, the mode of detection does impact on survival in
patients with equivalent NPI scores. This residual survival benefit is small but significant, and is likely to be due to differences in tumour
biology. Current prognostication tools may, therefore, overestimate the benefit of systemic treatments in screen-detected cancers
and lead to overtreatment of these patients.
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Breast cancer remains a major UK public health issue with over
40000 newly diagnosed patients and 15000 deaths per annum.
Following publication of initial trials that showed that mammo-
graphic screening could reduce breast cancer mortality (Shapiro
et al, 1971; Tabar et al, 1985), the National Health Service Breast
Screening Programme (NHSBSP) was introduced in 1988 in the
United Kingdom and offered 3 yearly mammographic screening
initially to women aged 50–65 years. The upper age limit is now 69
years and from 2008 screening onwards it will be offered to women
aged 47–73 years. A recent overview of published screening trials
has confirmed a reduction in breast cancer mortality of 21% in
woman attending for mammographic screening (Nystro ¨m et al,
2002). The rational for this survival benefit is that screening
enables breast cancers to be diagnosed at an earlier stage of
disease. It is now well documented that screen-detected cancers are
generally smaller, of lower grade and less likely to have axillary
lymph node involvement (Weaver et al, 2006).
The Nottingham Prognostic Index (NPI) (Todd et al, 1987), a
prognostic tool based on tumour size, grade and lymph node
status, allocates individual patients to one out of five prognostic
groups with quite different survival predictions. For many years,
it has been assumed that the survival benefit associated with
screen-detected cancers is due to stage shift, with these cancers
presenting in a better prognostic group and intuitively one would
expect that cancers, which have an equivalent NPI, would have
the same prognosis regardless of their mode (i.e., screening or
symptomatic) of detection. Two recent papers, however, have
suggested that screen detection confers an additional survival
benefit beyond stage shift (Shen et al, 2005) and reduces the risk of
systemic recurrence when compared with symptomatic cancers of
a similar stage (Joensuu et al, 2004). This current paper, therefore,
aims to examine whether a cancer detected by mammographic
screening confers additional prognostic benefit to the patient over
and above that expected by the improved NPI stage shift.
MATERIALS AND METHODS
Female patients diagnosed between 1998 and 2003 with invasive
breast cancer (ICD10 site code C50*), and aged between 50 and
70 years at diagnosis, were identified by the Eastern Cancer
Registration and Information Centre (ECRIC). During this period,
ECRIC covered a population of approximately 2.75 million people
in the counties of Bedfordshire, Cambridgeshire, Norfolk and
Suffolk. Mammographic screening status of these cancers was
determined by matching data from the 11 breast screening units in
the East of England with the ECRIC registry database. These
screening unit data were received by ECRIC via the East of England
Breast Screening Quality Assurance Reference Centre.
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sMode of detection has been classified as either screen detected
(including both prevalent and incident cases) or symptomatic
(regardless of whether the patients had ever been screened). We
identified 5604 female patients with breast cancer, with over 97%
confirmed histologically, and determined the current vital status of
these patients. The vital status of each individual patient in this
study was followed up actively by ECRIC in early 2007 by querying
the National Health Service Strategic Tracing Service. Thus, it is
expected that these data are substantially complete and reliable.
Data elements recorded by ECRIC include age at diagnosis,
pathological tumour size, number of nodes excised and status,
treatment type (wide local excision, mastectomy, axillary surgery,
radiotherapy, chemotherapy and hormone therapy) and index of
multiple deprivation based on patient’s electoral ward of residence.
The primary sources of registration and treatment data are reports
from all pathology laboratories and hospital patient notes, which
are viewed by registry staff who are either based at all major NHS
hospitals in the region or visit them on at least a monthly basis.
Both electronic and paper-based reports are received by the
registry, so a high level of completeness of registration is also
expected.
From the tumour size, lymph node status and histological grade,
we calculated the NPI for each case. The NPI has been validated in
other breast cancer populations and allows assessment of the effect
of different treatments in each of the five different prognostic
groups, excellent (NPIo2.4), very good (2.4oNPIo3.4), moderate
1 (3.4oNPIo4.4), moderate 2 (4.4oNPIo5.4) and poor
(NPIX5.4) (Sundquist et al, 1999). We estimated the effect of
continuous NPI in screen-detected and symptomatic disease, and
derived corresponding fitted 5-year survival curves.
Differences between screen-detected and symptomatic patients
with respect to categorical variables were assessed using the w
2 test.
For analysis of the effect of screen detection, we analysed data only
from subjects aged 50–69 years at diagnosis, the age range of the
NHSBSP. Survival was analysed using proportional hazards
regression (Cox, 1972). We first estimated the effect of screen
detection as compared with symptomatic diagnosis on survival
unadjusted, then adjusted for age and NPI. The method of
Freedman et al (1992) was used to estimate the percentage of the
effect of screen detection on survival that can be attributed to other
factors such as NPI.
RESULTS
Table 1 shows the frequencies by age and NPI for screen-detected
and symptomatic patients. Screen-detected patients were signifi-
cantly younger (Po0.001) and were more likely to have favourable
NPI categories (Po0.001) than the symptomatic patients. Screen-
detected patients were also less likely to have NPI unknown.
Figure 1 shows survival by time for screen-detected and
symptomatic patients. Table 2 shows the results of Cox’s
regression analysis from the univariate models for the separate
effects of each of NPI, age and detection on survival, and the
multivariate model with each factor adjusted for the two others.
Better survival was observed in younger patients, especially those
with favourable NPI and screen-detected patients. All three factors
had highly significant effects on survival in the univariate analyses
(Po0.001 in all cases).
Table 1 Age and NPI category frequencies by detection mode
Number of patients (%)
Factor Category Symptomatic Screen detected
Age (years) 50–59 1687 (50) 1260 (57)
60–70 1691 (50) 966 (43)
Total 3378 (100) 2226 (100)
NPI group Excellent 186 (5) 423 (19)
Good 474 (14) 682 (31)
Moderate 1 569 (17) 440 (20)
Moderate 2 598 (18) 213 (9)
Poor 418 (12) 94 (4)
Unknown 1113 (34) 374 (17)
Total 3378 (100) 2226 (100)
NPI¼Nottingham Prognostic Index.
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Figure 1 Survival by detection mode.
Table 2 Cox’s regression analysis from the univariate models for the separate effects of each of NPI, age and mode of detection on survival, and the
multivariate model with each factor adjusted for the two others
Factor Category Deaths
Relative hazard (95% CI)
univariate Cox’s regression results
Relative hazard (95% CI)
multivariate Cox’s regression results
Age (years) 50–59 339 1.00 (—) 1.00 (—)
60–70 443 1.41 (1.17–1.70) 1.36 (1.13–1.64)
NPI Excellent 18 1.00 (—) 1.00 (—)
Good 53 1.65 (0.96–2.82) 1.59 (0.93–2.72)
Moderate 1 73 2.54 (1.51–4.26) 2.36 (1.40–3.97)
Moderate 2 141 6.38 (3.94–10.42) 5.65 (3.43–9.30)
Poor 188 15.65 (9.64–25.40) 13.87 (8.46–22.73)
Detection mode Symptomatic 641 1.00 (—) 1.00 (—)
Screen detected 141 0.43 (0.34–0.53) 0.79 (0.63–0.99)
CI¼confidence interval; NPI¼Nottingham Prognostic Index.
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sIn the multivariate model, all three factors retained their
statistical significance, but the effect of screen detection on
survival was much attenuated after adjustment for age and NPI,
with the relative hazard changing from 0.43 to 0.79. Freedman’s
estimate of the proportion of the effect of screen detection on
survival accounted for by age and NPI was 72%.
Although there is some evidence that histological grade may
deteriorate as the tumour progresses and that early detection can
arrest this (Duffy et al, 1991), it is also at least partly an innate
biological feature. We, therefore, also estimated the effect of
adjustment for size and node status only. The adjusted relative
hazards for screen detection and the Freedman estimate of the
proportion of the screening effect accounted for by adjustment for
various factors are shown in Table 3. Adjustment for size and node
status takes account of 49% of the effect of screen detection on
survival, shifting the relative hazard from 0.43 to 0.66. Adjustment
for NPI (the addition of histological grade to size and node status)
accounts for 67% of the screen detection effect, shifting the relative
hazard to 0.76. Adjustment for both NPI and age accounts for 72%
of the effect and moves the relative hazard to 0.79.
The 5-year overall survival figures for all patients, and by mode
of detection, are shown in Table 4. The greatest absolute survival
benefit for screen-detected cancers is seen in the bottom two
prognostic groups with a 10% absolute difference in the moderate
2 group. Survival analysis by continuous NPI showed a small but
systematic survival benefit for screen-detected cancers at each NPI
value (Figure 2).
DISCUSSION
We analysed 5-year survival data of women aged 50–70 years
diagnosed with invasive breast cancer in the East of England. Our
results confirm a strong survival advantage of screening compared
with symptomatic detection. They show that the majority of this
effect can be attributed to a shift in NPI. This is best illustrated in
Figure 2, where there is a small survival benefit for screen
detection at each NPI value. After adjustment for NPI and age, only
28% of the screen detection survival advantage remained to be
explained. Some of this is likely to be due to residual lead-time and
length bias. In lead-time bias, screening advances the time of
diagnosis so there is an artificial increase in survival time from
diagnosis whatever the effect (or lack of effect) on the ultimate
time of death. Length bias is the phenomenon whereby slower
growing cancers remain in the preclinical detectable phase longer
than faster growing cancers, and therefore screening will inevitably
detect proportionally more slower growing, better prognosis
cancers than those seen in the symptomatic population. Although
it is likely that most of both biases should have been accounted for
by NPI shift, quantification of this is the subject of ongoing
research.
The remainder of the survival advantage is likely to be due
to additional biological differences between screen-detected
and symptomatic cancers including rates of hormone receptor
positivity, HER 2 status and other biological factors. A recent
tissue microarray study examined expression of a panel of 13
biomarkers (including ER, PR and HER2), in two independent case
series and found that only Bcl-2 retained prognostic significance
independent of NPI on multivariate analysis (Callagy et al, 2006).
It is possible, however, that a number of biological markers, that
on their own are not significant, contribute to the remaining 28%
survival advantage seen with screen-detected cancers and this is
the subject of ongoing research. The interesting point is that the
majority of the survival effect of screen detection is accounted for
by a shift in NPI, with only 28% attributable to other factors. These
results would appear to confirm previous studies that suggested
that screen detection was an independent prognostic factor for
both disease-specific survival (Shen et al, 2005) and distant
recurrence (Joensuu et al, 2004).
Accurate prognostication plays an essential role in the selection
of appropriate adjuvant therapy. At present, mode of detection is
not taken into account when calculating the risk of recurrence or
death or subsequent treatment benefits. If the survival data for all
patients is used to calculate absolute treatment benefits for patients
with screen-detected cancers, then it is possible that the potential
benefits will be overestimated (Table 4). This, in turn, may lead to
potential overtreatment of patients with screen-detected cancers.
The authors recognise that the number of patients with NPI
unknown is greater in the symptomatic group (34%) than the
screen-detected group (17%), but this is unlikely to significantly
impact on these findings.
These data confirm the known survival advantage for patients
with screen-detected cancers. They show that although most of this
advantage is due to a shift in NPI, the mode of detection does
impact on survival in patients with equivalent NPI scores. This
residual survival benefit is small but significant, and is likely to be
due to differences in tumour biology between screen-detected and
Table 3 Attenuation of the effect of screen detection on survival, after
adjustment for different factors
Factors
Relative hazard (95% CI), screen
detected vs symptomatic
% of screen
detection effect
None 0.43 (0.34–0.53) 0
Size and
node status
0.66 (0.53–0.82) 49
NPI 0.76 (0.60–0.95) 67
NPI, age
(years)
0.79 (0.63–0.99) 72
CI¼confidence interval; NPI¼Nottingham Prognostic Index.
Table 4 Five-year overall survival (%)
NPI All patients Symptomatic Screen detected
o2.4 96 94 98
2.4–3.39 93 93 94
3.4–4.39 90 89 93
4.4–5.39 79 78 88
5.4+ 58 58 65
NPI¼Nottingham Prognostic Index.
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Figure 2 Fitted 5-year survival by continuous NPI (P¼0.01).
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ssymptomatic cancers. Current prognostication tools that do not
include known biological markers may overestimate the benefit
of systemic treatments in screen-detected cancers and lead to
overtreatment of these patients. A prognostic tool combining
clinical, pathological and biological factors might allow more
accurate prognostication, and more appropriate systemic therapy,
for all patients with breast cancer regardless of their mode of
detection.
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